DescriptionCurator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364036 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BACITRACIN Approved UseUses first aid to help prevent infection in: •minor cuts •scrapes •burns Launch Date1948 |
|||
Curative | CORTISPORIN Approved UseFor the treatment of corticosteroid-responsice dermatoses with secondary infection. Launch Date1957 |
|||
Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. Launch Date1968 |
PubMed
Title | Date | PubMed |
---|---|---|
The Action of Bacitracin and Subtilin on Treponema pallidum in Vitro and in Vivo. | 1948 Mar |
|
The Use of Bacitracin in Experimental Clostridium Welchii Infection in Guinea Pigs. | 1949 Oct |
|
Cholesterol 7alpha-hydroxylase. 2. Biochemical properties and participation of endogenous cholesterol in the assay in vitro. | 1975 Jun 16 |
|
Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms. | 1999 May |
|
Plasma apolipoprotein B-48, hepatic apolipoprotein B mRNA editing and apolipoprotein B mRNA editing catalytic subunit-1 mRNA levels are altered in zinc-deficient rats. | 1999 Oct |
|
Copper transport and its defect in Wilson disease: characterization of the copper-binding domain of Wilson disease ATPase. | 2000 Apr |
|
Zinc and copper modulate differentially the P2X4 receptor. | 2000 Apr |
|
Chelation of zinc amplifies induction of growth hormone mRNA levels in cultured rat pituitary tumor cells. | 2000 Feb |
|
The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures. | 2000 Feb 15 |
|
Zinc and cadmium can promote rapid nuclear translocation of metal response element-binding transcription factor-1. | 2000 Mar 31 |
|
Cadmium mutagenicity and human nucleotide excision repair protein XPA: CD, EXAFS and (1)H/(15)N-NMR spectroscopic studies on the zinc(II)- and cadmium(II)-associated minimal DNA-binding domain (M98-F219). | 2000 May |
|
Heterogeneity of GABA(A) receptor-mediated responses in the human IMR-32 neuroblastoma cell line. | 2000 May 15 |
|
Increased protein intake during recovery from zinc deficiency is accompanied by alterations in hypothalamic growth hormone releasing factor and somatostatin. | 2001 |
|
Dietary zinc deficiency increases uroguanylin accumulation in rat kidney. | 2001 Apr |
|
Tyrphostin [correction of Tryphostin] AG879, a tyrosine kinase inhibitor: prevention of transcriptional activation of the electrophile and the aromatic hydrocarbon response elements. | 2001 Jan 15 |
|
Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. | 2001 Mar |
|
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
Zinc depletion reduced Egr-1 and HNF-3beta expression and apolipoprotein A-I promoter activity in Hep G2 cells. | 2002 Aug |
|
Isolation of GIF from porcine brain and studies of its zinc transfer kinetics with apo-carbonic anhydrase. | 2002 Dec |
|
Purification and characterization of cytosolic glycerol-3-phosphate dehydrogenase from skeletal muscle of jerboa (Jaculus orientalis). | 2002 Feb |
|
Attenuation of both apoptotic and necrotic actions of cadmium by Bcl-2. | 2002 Jan |
|
Allosteric modulation of beta2-adrenergic receptor by Zn(2+). | 2002 Jan |
|
Role of a copper-specific metallothionein of the blue crab, Callinectes sapidus, in copper metabolism associated with degradation and synthesis of hemocyanin. | 2002 Jan 15 |
|
Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone. | 2002 Jan 15 |
|
Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation. | 2002 Jul 5 |
|
Partitioning of accumulated trace metals in the talitrid amphipod crustacean Orchestia gammarellus: a cautionary tale on the use of metallothionein-like proteins as biomarkers. | 2002 Jun |
|
White-sided dolphin metallothioneins: purification, characterisation and potential role. | 2002 Mar |
|
Brain-specific metallothionein-3 has higher metal-binding capacity than ubiquitous metallothioneins and binds metals noncooperatively. | 2002 May 14 |
|
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. | 2002 Nov |
|
Zinc transporters in the rat mammary gland respond to marginal zinc and vitamin A intakes during lactation. | 2002 Nov |
|
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). | 2002 Oct 25 |
|
Interrelationships among brain, endocrine and immune response in ageing and successful ageing: role of metallothionein III isoform. | 2003 Apr |
|
Effect of chromium on apolipoprotein A-I expression in HepG2 cells. | 2003 Apr |
|
Mechanisms of Zn(2+)-induced signal initiation through the epidermal growth factor receptor. | 2003 Aug 15 |
|
Redox labile site in a Zn4 cluster of Cu4,Zn4-metallothionein-3. | 2003 Aug 19 |
|
Activation of the rainbow trout metallothionein-A promoter by silver and zinc. | 2003 Jan |
|
Differential effects of zinc on functionally distinct human growth hormone mutations. | 2003 Jul |
|
In vitro effect of metal ions on the activity of two amphibian glyceraldehyde-3-phosphate dehydrogenases: potential metal binding sites. | 2003 Jun |
|
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase. | 2003 May 2 |
|
Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family. | 2003 Oct 3 |
|
Thymulin evokes IL-6-C/EBPbeta regenerative repair and TNF-alpha silencing during endotoxin exposure in fetal lung explants. | 2004 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment: Bacitracin can be used as ophtalmic solution (0.025mg/ml) for the treatment of superficial ocular infections.
400 units, topically
Route of Administration:
Topical
Substance Class |
Mixture
Created
by
admin
on
Edited
Fri Dec 15 16:04:25 GMT 2023
by
admin
on
Fri Dec 15 16:04:25 GMT 2023
|
Record UNII |
89Y4M234ES
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 333.120
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
||
|
CFR |
21 CFR 558.78
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
||
|
NCI_THESAURUS |
C258
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
||
|
CFR |
21 CFR 333.110
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
||
|
CFR |
21 CFR 558.78
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
||
|
EPA PESTICIDE CODE |
6309
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
||
|
CFR |
21 CFR 520.154C
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB00653MIG
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | |||
|
215-787-8
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | |||
|
1048007
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | |||
|
BACITRACIN ZINC
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Soluble in 900 parts of water and in 500 parts of ethanol (~750 g/l) TS; very slightly soluble in ether R. Category: Antiinfective drug. Storage: Bacitracin zinc should be kept in a tightly closed container, protected from light, and stored at a temperature not exceeding 25 ?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude microorganisms. Labelling: The designation sterile Bacitracin zinc indicates that the substance complies with the additional requirements for sterile Bacitracin zinc and may be used for other sterile applications. Additional information: Bacitracin zinc is hygroscopic. Definition: Bacitracin zinc is a zinc complex of bacitracin, a polypeptide produced by the growth of an organism of the licheniformis group of Bacillus subtilis. The main components are Bacitracin A, B1 and B2. Bacitracin zinc contains not less than 55 International Units of bacitracin per mg, calculated with reference to the dried substance. | ||
|
1405-89-6
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | |||
|
C28857
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | |||
|
m2199
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
89Y4M234ES
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | |||
|
DBSALT001356
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200558
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | |||
|
89Y4M234ES
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | |||
|
DTXSID00858760
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | |||
|
11417
Created by
admin on Fri Dec 15 16:04:25 GMT 2023 , Edited by admin on Fri Dec 15 16:04:25 GMT 2023
|
PRIMARY | RxNorm |
All of the following components must be present:
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
http://apps.who.int/phint/pdf/b/Jb.6.1.41.pdf
|